Final Assessment Report, External Comments/Answers and Project Plan for pharma JA on Regorafenib (Stivarga©)

We are pleased to announce that the pharmaceutical Joint Rapid Assessment on “Regorafenib (Stivarga©) indicated as monotherapy for the treatment of adult patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib” is now available. The final assessment report was published in October 2017. 

Find the documentation provided by the authoring team here.